KYMR News and Press, Kymera Therapeutics Inc.

2024-07-16 04:58:20 ET Summary Kymera Therapeutics is a protein degradation specialist drug developer with promising Phase 1 and 2 stage protein degraders targeting various diseases. A partnership with Sanofi includes potential milestone payments of up to $1.48 billion for IRAK4 p...

2024-07-12 19:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-07-09 13:30:00 ET Shares of Kymera Therapeutics (NASDAQ: KYMR) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi , plans to expand the ongoing phase 2 s...

WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside ...

2024-07-09 06:02:27 ET More on related stocks: Intel: Long-Term Success Seems Likely, But The Path Forward Remains Uncertain Intel: Why The Dip Is Not Fair Intel: Between A Rock (NVIDIA) And A Hard Place (AMD) BP warns of up to $2B impairment, lower refining ...

2024-07-08 16:17:01 ET More on Kymera Therapeutics, Sanofi, etc. Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting Sanofi: A Leader In Life-Saving Vaccines And Treatments Kymera Therapeutics, Inc. (KYMR) Q1 2024 Earnings Call Transcript Sanofi, Reg...

WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that following a review of preliminary KT-47...

2024-06-20 08:45:59 ET Palm Beach, FL – June 20, 2024  – Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of pancreatic adenocar...

PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of panc...

KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and positive immunomodulatory effect achieved in blood and tumor KT-333 was well-t...